Masseter neurotoxin is one of the highest-demand treatments an injector offers, and one of the easiest to do adequately and hard to do well. The margin between a clean jaw-tension result and a changed smile is a centimeter and a plane. This is how I think about it.
Surface anatomy before anything else
Have the patient clench. The masseter belly pops up as a firm, mobile mass over the ramus and angle of the mandible. Palpate the borders with the patient clenching and relaxed — you are mapping the bulk of the muscle, not injecting a landmark you read in a diagram.
The muscle you are treating sits inside a safe zone: below and behind a line drawn from the tragus to the oral commissure, and anterior to the posterior border of the mandible. Stay in that box and you keep product away from the risorius and zygomaticus — the smile muscles that, if weakened, produce the classic "my smile changed" complaint.
Depth and plane
The masseter is thick. Injections are deep — down to the muscle belly, needle roughly perpendicular, hub often near the skin in a hypertrophic patient. Superficial placement is not "safer"; it is how product diffuses forward into muscles you never intended to touch. Deep and posterior is the discipline.
Dosing is a range, not a recipe
Commonly cited starting ranges sit in the ballpark of low-to-mid tens of units of onabotulinum-equivalent per side, split across two to three points, adjusted for muscle bulk. I am deliberately not handing you a single number, because the honest answer is:
- Hypertrophy — a dense, athletic masseter takes more than a thin one.
- Goal — bruxism and tension relief is a different endpoint than visible slimming, which takes serial treatment as the muscle atrophies over months.
- History — retreatment intervals and prior response reset the math every time.
Always dose to the product's instructions for use and your own training. Under-dose, review at two weeks, and add. You cannot remove neurotoxin.
The two mistakes
- The changed smile. Product placed too anterior or too superficial migrates into the smile complex. The fix is prevention: respect the anterior border, inject deep, and keep your most anterior point well inside the safe zone.
- Paradoxical bulging. Partial treatment weakens the main belly while accessory bundles stay active, and the patient reports a new bulge on chewing. This is a mapping failure — you treated a point, not the muscle.
Consult like a clinician
Masseter treatment changes the lower-face silhouette over months. Photograph in repose and clenched, set the expectation that slimming is gradual and serial, and document the goal in the patient's words. A masseter patient who expected a jawline overnight is a retention problem you created at the consult, not the injection.